Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia
Status:
Unknown status
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
Severe aplastic anemia (SAA)is characterized by the depletion of hematopoietic precursors
associated with life-threatening complications. High-dose cyclophosphamide has been found to
yield a complete response (CR) in adults and children with SAA.However, the optimal dosage of
cyclophosphamide for patients in childhood remains unclear. So we explore the ideal dosage of
cyclophosphamide for the treatment of children with SAA.